MedTrace Logo

Study Of Celecoxib In Healthy Subjects

NCT00994461 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2021-02-02

Study results available
· View outcomes & findings →

Summary

A study to confirm the superiority of celecoxib 100 mg BID to loxoprofen 60 mg TID in the incidence of gastroduodenal endoscopic ulcers after 2 weeks treatment.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Celecoxib

Celecoxib 100mg tablet twice a day with meal for 2 weeks

DRUG

Loxoprofen

Loxoprofen 60mg tablet three times a day with meal for 2 weeks

DRUG

Placebo

Placebo tablet three times a day with meal for 2 weeks

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00994461 on ClinicalTrials.gov